

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

January 8, 2026
David Bautz, PhD
312-265-9471
dbautz@zacks.com

scr.zacks.com

101 N. Wacker Drive, Chicago, IL 60606

FibroBiologics, Inc.

(FBLG-NASDAQ)

FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26

Based on our probability adjusted DCF model that takes into account potential future revenues of CybroCell, CYMS101, CYWC628, and psoriasis treatment FBLG is valued at \$6.50 per share. This model is highly dependent upon the continued clinical success of the company's development candidates and will be adjusted accordingly based upon future clinical results.

Current Price (01/08/26) \$0.34
Valuation **\$6.50**

OUTLOOK

In the past few weeks, FibroBiologics, Inc. (FBLG) has announced multiple important advancements, including HREC approval to conduct a Phase 1/2 trial of CYWC628 in diabetic foot ulcers (DFUs), filing an IND to seek clearance for a Phase 1/2 clinical trial of CYP317 for the treatment of moderate to severe psoriasis, announcing positive preclinical results for a fibroblast therapy for degenerative disc disease, closing multiple registered direct offerings, and paying off all outstanding debt. Looking ahead to 2026, we anticipate the initiation of the Phase 1/2 trial in DFUs in the first quarter of 2026, the potential for IND clearance for CYP317, and the advancement of CYMS101 toward an IND submission for the treatment of multiple sclerosis.

SUMMARY DATA

52-Week High \$2.26
52-Week Low \$0.22
One-Year Return (%) -83.31
Beta -0.54
Average Daily Volume (sh) 3,245,262

Shares Outstanding (mil) 67
Market Capitalization (\$mil) \$23
Short Interest Ratio (days) N/A
Institutional Ownership (%) 0
Insider Ownership (%) 13

Annual Cash Dividend \$0.00
Dividend Yield (%) 0.00

5-Yr. Historical Growth Rates

Sales (%) N/A
Earnings Per Share (%) N/A
Dividend (%) N/A

P/E using TTM EPS N/A

P/E using 2026 Estimate N/A

P/E using 2027 Estimate N/A

Risk Level

High

Type of Stock
Industry

Small-Growth
Med-Biomed/Gene

ZACKS ESTIMATES

Revenue

(in millions of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	0.0 A	0.0 A	0.0 A	0.0 A	0.0 A
2025	0.0 A	0.0 A	0.0 A	0.0 E	0.0 E
2026					0.0 E
2027					0.0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	-\$0.27 A	\$0.03 A	-\$0.01 A	-\$0.11 A	-\$0.34 A
2025	-\$0.14 A	-\$0.12 A	-\$0.13 A	-\$0.07 E	-\$0.45 E
2026					-\$0.26 E
2027					\$0.24 E

WHAT'S NEW

Business Update

Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial

In November 2025, FibroBiologics, Inc. (FBLG) announced that it has received both public and private Human Research Ethics Committee (HREC) approvals in Australia for the planned Phase 1/2 clinical trial of CYWC628 for the treatment of refractory Diabetic Foot Ulcers (DFU). The approval allows for enrollment of 120 patients across 10 clinical sites in Australia. Now that HREC approval has been granted, the company has fulfilled all necessary regulatory approvals and required filings prior to proceeding with the clinical trial, which we anticipate initiating in the first quarter of 2026.


The trial is a multicenter, randomized study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics topically administered allogenic fibroblast therapy, CYWC628. Study subjects will receive up to 12 weeks of treatment using either standard of care (SoC) plus a high or low dose of CYWC628, or SoC alone. Study outcomes include wound healing, efficacy of response, and safety parameters. An interim analysis will be conducted after a predefined number of participants complete six weeks of treatment to assess primary safety and efficacy endpoints. The results from the interim analysis could be available in mid-2026, with topline results expected before the end of 2026.

DFUs cause significant morbidity for the 6.3% of diabetic adults (~33 million) that develop them. Of those, 20% will require lower extremity amputation and 10% will die within the first year of their first DFU. In addition, once a DFU forms there is a high rate of recurrence, both at one year (40%) and three years (70%).

Fibroblasts have excellent therapeutic potential in the treatment of DFUs due to the critical role they play in every stage of wound healing, including hemostasis, inflammation, proliferation, and remodeling. Importantly, fibroblasts are the key cells that secrete extracellular matrix proteins that maintain all the tissues and organs in the body.

Role of Fibroblasts in Wound Healing

Fibroblasts play critical roles in every stage of wound healing



Ciabat, Francesca et al. "Role of fibroblasts in wound healing and tissue remodeling on Earth and in space." Frontiers in bioengineering and biotechnology vol. 10 958381. 4 Oct. 2022


Source: FibroBiologics, Inc.

The company does not utilize single cell fibroblasts for treatment but instead a fibroblast spheroid, which is composed of approximately 3,000 fibroblasts and is administered to the top of the wound at which time the cells migrate from the surface of the wound and release various cytokines and growth factors to initiate the wound healing process. The use of spheroids is more practical from a therapeutic perspective as they have higher viability than single cells, they don't require pre-culturing before administration, they can be easily frozen and thawed, and they have a significantly higher potency and efficacy compared to single cells.

FibroBiologics has compiled a robust pre-clinical data set showing the efficacy of fibroblast spheroids in the treatment of wounds. For example, the following figure shows results using a diabetic mouse model in which administration of fibroblasts led to a statistically significant average 83.8% wound closure by Day 19 compared to 66.0% for Grafix™ and only 51.2% for control.

Significantly Improved Wound Closure Rate with Multiple Administration

Comparison with an FDA approved DFU Treatment and Control



At day 19: **83.8% average wound closure for fibroblast spheroids** compared with 66.0% for Grafix™ and 51.2% for Control

Note: * indicates level of statistical significance with a p value of ≤ 0.05
 ** indicates level of statistical significance with a p value of ≤ 0.01

Source: FibroBiologics, Inc.

While wound healing is important, the quality of the wound healing is just as important. FibroBiologics has data on seven key biomarkers that are key to demonstrating the quality of the wound healing. Fibroblast treatment shows much better re-epithelialization, granulation, cell proliferation, neo-vascularization, recruitment and proliferation of fibroblasts, keratinocyte migration, and epithelial-mesenchymal transition. Intriguingly, even though the fibroblast spheroids are administered topically, there appears to be a systemic effect on cytokine levels, including IL-6, TNF- α , IL-1 β , and IL-10.

The use of fibroblast spheroids for wound healing can be thought of as a platform technology. In addition to the treatment of DFUs, fibroblast spheroids could also be used for the treatment of burns and surgical wounds.

In regards to safety, the company has performed a number of experiments to examine any potential adverse events associated with fibroblast-based therapy. The cells do not graft into tissue. Following application, the cells stay on the surface of the wound and initiate the healing process before gradually dying off within four days of treatment. In addition, there is no impact on CBC, WBC, liver function, or kidney function, thus showing that administration of fibroblasts appears to be quite safe.

Positive Preclinical Results in Degenerative Disc Disease Animal Model

On January 5, 2026, FibroBiologics announced positive preclinical results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) therapy that showed superior improvement in recovering intervertebral disc integrity and preventing degeneration in animal models of degenerative disc disease. The condition affects millions of adults in the United States and is a leading cause of chronic back pain and disability.

In the current studies, the efficacy of FSdC spheroids was compared to 2D fibroblasts and fibroblast spheroids. The data showed that FSdC spheroids achieved the most statistically significant difference from control with a P value of 0.00015, compared to a P value of 0.036 for 2D fibroblasts and 0.068 for fibroblast spheroids. FSdC spheroids also showed the highest level of intervertebral disc height recovery after 12 weeks of treatment compared to the other two fibroblast therapies. These results suggest FSdC spheroids may offer disease-modifying effects and not just alleviation of symptoms, based on their ability to sustain the highest average disc size index across all time points. In addition, these results de-risk the platform as it advances toward clinical trials and supports an additional pipeline indication for the company's fibroblast-based technology.

IND Application Filed for CYP317 in Psoriasis

On December 31, 2025, FibroBiologics announced the filing of an Investigational New Drug (IND) application with the U.S. FDA seeking regulatory clearance to initiate clinical trials of CYP317 for the treatment of

moderate to severe psoriasis. This filing is based in part on positive IND-enabling preclinical results demonstrating the potential for fibroblast spheroids to significantly reduce psoriasis disease severity and relapse in preclinical models. For example, a single dose of CYPS317 was comparable or better to multiple doses of an anti-IL-23 monoclonal antibody and yielded significant reduction in disease recurrence. Following regulatory clearance of the IND, FibroBiologics intends to pursue a clinical development program for CYPS317 with a near-term goal of initiating first-in-human trials.

Financial Update

During November and December 2025, FibroBiologics raised gross proceeds of approximately \$7.2 million:

- On November 19, 2025, the company raised approximately \$4 million from the sale of 3.54 million shares of its common stock and pre-funded warrants to purchase approximately 8.57 million shares of common stock at a purchase price of \$0.3303 per share. In addition, the company issued and sold warrants to purchase one share of common stock for each share of common stock or pre-funded warrant purchased in the offering, for up to 12,110,203 shares of common stock. The warrants have an exercise price of \$0.3303 per share, will be exercisable beginning on the date of approval by company stockholders to issue the shares upon exercise of the warrants and will expire five years following the date of stockholder approval.
- On November 25, 2025, the company raised approximately \$1.5 million in gross proceeds from the sale of 4,477,614 shares of its common stock at a price of \$0.335 per share. In addition, the company issued and sold warrants to purchase 4,477,614 shares of common stock at an exercise price of \$0.335 per share. The warrants will be exercisable beginning on the date of approval by company stockholders to issue the shares upon exercise of the warrants and will expire five years following the date of stockholder approval.
- On December 16, 2025, the company raised approximately \$1.7 million in gross proceeds from the sale of 5,227,275 shares of its common stock at an offering price of \$0.33 per share. In addition, the company issued and sold warrants to purchase 5,227,275 shares of common stock at an exercise price of \$0.33 per share. The warrants will be exercisable beginning on the date of approval by company stockholders to issue the shares upon exercise of the warrants and will expire five years following the date of stockholder approval.

In November 2025, FibroBiologics announced it has paid all amounts outstanding under the convertible promissory notes issued to YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP pursuant to the Standby Equity Purchase Agreement (SEPA) entered into in December 2024 between the company and Yorkville. Yorkville advanced \$15 million (of up to \$25 million total under the SEPA) to the company in three equal tranches of Notes. The Notes are no longer outstanding and there will be no further conversions into shares of the company's common stock. The SEPA remains in place until Dec. 20, 2026 and it allows FibroBiologics to sell, at its discretion, an additional \$10 million in common stock to Yorkville.

Conclusion

FibroBiologics continues to execute on its business plan with the expected initiation of the Phase 1/2 clinical trial of CYWC628 in the first quarter of 2026, the IND filing for CYPS317 for the treatment of psoriasis, the recent financings, and paying off all outstanding debt to clean up its balance sheet. We look forward to results from the CYWC628 trial, with interim results possible in mid-2026 and topline results expected before the end of the year. After incorporating the recent financings into our model, our valuation is now at \$6.50 per share.


PROJECTED FINANCIALS

FibroBiologics, Inc.	2024 A	Q1 A	Q2 A	Q3 A	Q4 E	2025 E	2026 E	2027 E
CybroCell	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
CYMS101	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
CYWC628	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Psoriasis	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
License and other revenues	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Total Revenues	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Cost of revenues	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Research & development	\$4.5	\$1.8	\$2.0	\$2.8	\$1.4	\$8.0	\$6.5	\$7.5
General & administrative	\$9.2	\$2.8	\$2.4	\$2.2	\$2.2	\$9.6	\$9.0	\$9.5
Operating Income	(\$13.7)	(\$4.5)	(\$4.5)	(\$5.0)	(\$3.6)	(\$17.7)	(\$15.5)	(\$17.0)
Non-Operating Expenses (Net)	\$2.6	(\$0.4)	(\$0.2)	(\$0.7)	\$0.0	(\$1.3)	\$0.0	\$0.0
Pre-Tax Income	(\$11.2)	(\$5.0)	(\$4.7)	(\$5.8)	(\$3.6)	(\$19.0)	(\$15.5)	(\$17.0)
Deemed Dividend	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Income Taxes	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Net Income	(\$11.2)	(\$5.0)	(\$4.7)	(\$5.8)	(\$3.6)	(\$19.0)	(\$15.5)	(\$17.0)
<i>Net Margin</i>	-	-	-	-	-	-	-	-
Reported EPS	(\$0.34)	(\$0.14)	(\$0.12)	(\$0.13)	(\$0.07)	(\$0.45)	(\$0.26)	(\$0.24)
<i>YOY Growth</i>	-	-	-	-	-	-	-	-
Basic Shares Outstanding	32.9	36.7	38.6	43.1	51.5	42.5	60.0	70.0

Source: Zacks Investment Research, Inc.

David Bautz, PhD

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.

SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover.

SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.